Development and validation of a stereoselective liquid chromatography–tandem mass spectrometry assay for quantification of S- and R-metoprolol in human plasma

Jensen, Berit Packert; Sharp, Caroline F.; Gardiner, Sharon J.; Begg, Evan J.

doi:10.1016/j.jchromb.2008.02.006

Cited by 47 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some authors only investigated the absolute matrix effect and did not evaluate the effect of matrices from different sources [31,[58][59][60][61][62][63][64][65][66][67][68]. Cao et al [62] have quantified methyl protodioscin, a natural furostanol saponin with antitumor activity, in rat plasma after PPT.…”

Section: Literature Overviewmentioning

confidence: 99%

Validation of bioanalytical LC–MS/MS assays: Evaluation of matrix effects

Eeckhaut

Lanckmans

Sarre

et al. 2009

Journal of Chromatography B

678

379

View full text Add to dashboard Cite

Section: Literature Overviewmentioning

confidence: 99%

Validation of bioanalytical LC–MS/MS assays: Evaluation of matrix effects

Eeckhaut

Lanckmans

Sarre

et al. 2009

Journal of Chromatography B

678

379

View full text Add to dashboard Cite

“…A chiral liquid chromatographytandem mass spectrometry assay was developed to measure S-and R-metoprolol concentrations in plasma. 37 A standard curve over the range of 0.5-50 mg l À1 was used, with samples containing 450 mg l À1 diluted with blank plasma. Each plasma sample was analyzed in triplicate.…”

Section: S-and R-metoprolol Concentrationsmentioning

confidence: 99%

CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure

et al. 2009

View full text Add to dashboard Cite

The aims of this study were to examine the relationships between CYP2D6 genotype and metoprolol dose, S-and R-metoprolol concentrations and clinical effects in patients with systolic heart failure. Data were obtained for 52 subjects, of which 27 had 2 functional alleles (24/27, CYP2D6*1/*1), 22 had 1 functional allele (18/22, CYP2D6*1/*4) and 3 had no functional alleles (CYP2D6*4/*4). Median dose-adjusted concentrations of S-metoprolol (active) were 6.3-and 3.2-fold higher in subjects with zero or one functional allele (P ¼ 0.016 and P ¼ 0.006), respectively, compared with subjects with two functional alleles. For the R-enantiomer (inactive), these concentrations were 10.7-and 3.7-fold higher (P ¼ 0.013 and P ¼ 0.003), respectively. Despite clear gene-concentration differences, no relationships between CYP2D6 genotype and dose or clinical effects could be shown. Although the number with no functional alleles was too small (n ¼ 3) to show effects, in patients with 1 functional allele other sources of variance are likely to be obscuring differences in clinical effects.

show abstract

“…Furthermore, low volumes of plasma and urine (0.5 mL) are used in the proposed method, which can be advantageous in clinical pharmacokinetic studies. In the other methods, especially it has been worked with 1.0 or 0.9 mL of plasma [3,7,9,12].…”

Section: Applicationmentioning

confidence: 99%

“…Several methods have been reported for determination of metoprolol including GC-MS [3][4][5], HPLC [6][7][8][9][10], LC-MS [11][12][13] and LC-MS-MS [14] in human plasma and other biological fluids.…”

Section: Introductionmentioning

confidence: 99%

Determination of metoprolol in human plasma and urine by high‐performance liquid chromatography with fluorescence detection

Yılmaz

Aşçı

Arslan

2010

J of Separation Science

View full text Add to dashboard Cite

A simple, specific and sensitive HPLC method has been developed for the determination of metoprolol in human plasma and urine. Separation of metoprolol and atenolol (internal standard) was achieved on an Ace C(18) column (5 microm, 250 mm x 4.6 mm id) using fluorescence detection with lambda(ex)=276 nm and lambda(em)=296 nm. The mobile phase consists of methanol-water (50:50, v/v) containing 0.1% TFA. The analysis was performed in less than 10 min with a flow rate of 1 mL/min. The assay was linear over the concentration range of 3-200 and 5-300 ng/mL for plasma and urine, respectively. The LOD were 1.0 and 1.5 ng/mL for plasma and urine, respectively. The LOQ were 3.0 and 5.0 ng/mL for plasma and urine, respectively. The extraction recoveries were found to be 95.6 +/- 1.53 and 96.4 +/- 1.75% for plasma and urine, respectively. Also, the method was successfully applied to three patients with hypertension who had been given an oral tablet of 100 mg metoprolol.

show abstract

Development and validation of a stereoselective liquid chromatography–tandem mass spectrometry assay for quantification of S- and R-metoprolol in human plasma

Cited by 47 publications

References 22 publications

Validation of bioanalytical LC–MS/MS assays: Evaluation of matrix effects

Validation of bioanalytical LC–MS/MS assays: Evaluation of matrix effects

CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure

Determination of metoprolol in human plasma and urine by high‐performance liquid chromatography with fluorescence detection

Contact Info

Product

Resources

About